1. Home
  2. DRTS vs SVRA Comparison

DRTS vs SVRA Comparison

Compare DRTS & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$13.34

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Savara Inc.

SVRA

Savara Inc.

SELL

Current Price

$4.35

Market Cap

1.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DRTS
SVRA
Founded
2015
2007
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
DRTS
SVRA
Price
$13.34
$4.35
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
★ $17.80
$11.06
AVG Volume (30 Days)
471.5K
★ 2.4M
Earning Date
11-19-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,235.59
$4,336.88
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.43
$3.86
52 Week High
$15.79
$7.01

Technical Indicators

Market Signals
Indicator
DRTS
SVRA
Relative Strength Index (RSI) 54.48 45.28
Support Level $13.73 $4.13
Resistance Level $15.23 $5.53
Average True Range (ATR) 0.66 0.31
MACD 0.10 0.03
Stochastic Oscillator 92.31 52.74

Price Performance

Historical Comparison
DRTS
SVRA

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Share on Social Networks: